摘要
目的 探讨I～Ⅱ期乳头状甲状腺癌（PTC）患者肿瘤组织中BRAF基因V600E突变情况,并分析其与临床病理特征及预后的关系.方法 采用RT-PCR法检测374例Ⅰ～Ⅱ期PTC患者组织样本中BRAF基因V600E突变,并分析其与临床病理特征及预后的关系.结果 374例PTC患者标本中BRAF基因V600E的突变率为40.37％ （151/374）.BRAF基因V600E突变与包膜侵犯、多灶、多次131Ⅰ治疗相关（P＜0.05）.374例PTC患者中31例复发,复发患者中有BRAF基因V600E突变的22例.31例复发病例中,BRAF基因V600E突变患者的中位生存期为5.3年（95％ CI：3.9～6.7年）,未突变患者为7.0年（95％ CI：5.1～8.9年）,差异无统计学意义（P＞0.05）.Logistic多因素回归分析显示,BRAF基因V600E突变及包膜侵犯是Ⅰ～Ⅱ期PTC患者复发的独立危险因素（P＜0.05）.结论 BRAF基因V600E突变可能是Ⅰ～Ⅱ期PTC患者预后的一项重要预测指标.
Objective To investigate the status of BRAFV600E mutation in stage Ⅰ-Ⅱ papillary thyroid cancer（PTC） and evaluate the correlation between BRAFV600E mutation and clinicopathological characteristics and prognosis.Methods The BRAFV600E mutation of stage Ⅰ-Ⅱ PTC was detected by RT-PCR.The relationship was analyzed between BRAFV600E mutation and clinicopathological characteristics and prognosis of PTC.Results The BRAFV600E mutation rate in 374 cases of PTC was 40.37% （151/374）.The BRAFV600E mutation correlated with capsule invasion,multifocality,multiple radioiodine courses （P 〈 0.05）.Thirty-one patients were recurrent in 374 cases of PTC,including 22 patients with BRAFV600E mutation.The median survival time was 5.3 years（95% CI：3.9-6.7） in the recurrent PTC patients with BRAFV600E mutation which had shorter trend compared with 7.0 years（95% CI：5.1-8.9） in the patients without mutation.But no statistical difference was found.The BRAFV600E mutation and capsule invasion were prognostic factors in predicting the recurrence of the disease by multiple logistic regression test（P 〈 0.05）.Conclusion The BRAFV600E mutation may be an independent prognostic factor in predicting the prognosis of stage Ⅰ-Ⅱ PTC patients.
出处
《临床肿瘤学杂志》
CAS
2013年第12期1100-1103,共4页
Chinese Clinical Oncology
